In the case of all-cause mortality, a multinational cohort study with over 2 million patients with T2DM receiving insulin and a follow-up time of 5 years showed a significant reduction in all-cause mortality in those with SGLT-2i and GLP-1RA combination therapy as compared to those treated with either SGLT-2i or GLP-1RA alone [50]
Both medications are injectable GLP-1 receptor agonists used for type 2 diabetes management and weight loss, but they have several important differences: Mounjaro (tirzepatide) : Functions as both a GIP and GLP-1 receptor agonist, targeting two hormone pathways Ozempic (semaglutide) : Works solely as a GLP-1 receptor agonist, targeting one hormone pathway Based on the Phase 3 SURPASS-2 clinical study: Mounjaro : Approved for type 2 diabetes Ozempic : Approved for: Mounjaro : Ozempic : For expats and travelers in Mexico, both medications require a prescription, but Mounjaro may be preferred by those seeking more significant weight loss or better glycemic control
Future studies should prioritize adequately powered trials with standardized dosing, longer follow-up periods, and clinically meaningful endpoints to clarify the translational relevance of HTY
The reason for this is the extrapolymeric substances which are the basis of the biofilm 'slime', and lipopolysaccharides are found in abundance
In the meantime, the GLP-1 Collective is raising money to help people pay for their prescriptions
Peptides and Adjuvants for Augmentation of Fibroblast Therapy for Coronavirus
.png.jpg)
